This is the first study to investigate the relationship between the Gly389Arg ADRB1 variant and obesity . These data also suggest that blocking ADRB-mediated angiogenesis could have therapeutic implications for the management of ovarian cancer. METHODS AND RESULTS: Patients with essential hypertension and echocardiographically diagnosed LVH were included in a double-blind study to receive treatment with either the angiotensin II type 1 receptor (AT1-receptor) antagonist irbesartan (n = 41), or the beta-1 adrenergic receptor blocker atenolol (n = 43) as monotherapy for 3 months.